Chlamydia Treatment_ Is it the End of the Antibiotic Era

1. Chlamydia Treatment: Is it the End of the Antibiotic Era? The most prevalent bacterial sexually transmitted infection worldwide is chlamydia. Infections with Chlamydia are asymptomatic in 50–88% of men and women, and 46% of infections spontaneously disappear after a year. Men can get epididymitis and epididymo-orchitis from persistent chlamydia infection, while women can develop pelvic inflammatory illness, ectopic pregnancy, and tubal infertility. Chlamydia infection can occur at any age, although it is more common in people under 25, with rates of diagnosis rising in both women and men between the ages of 16 and 24. For many years, Azithromycin has been recommended as the first-line therapy for chlamydia infection. Azithromycin resistance may, however, be developing due to its pervasive usage in treating infections, according to recent studies. Data from observational studies contrasting azithromycin with doxycycline for the treatment of chlamydia showed that azithromycin had a higher failure rate than doxycycline. The CDC has modified its STI management recommendations for chlamydia in 2021 to address the issue of resistance development. The recommended medication for chlamydia treatment is now oral doxycycline 100 mg twice daily for 7 days, per these updated recommendations. Antibiotic resistance and an increase in infection cases have emerged as a global threat. Due to more accurate tests and more chlamydia testing during the past ten years, the number of identified instances of

2. infection has skyrocketed. According to the Chlamydia Epidemiology Report by DelveInsight, there were more than 3 million cases in seven main markets in 2021, and it is predicted that there could be up to 5 million cases by 2032. Among the seven major markets, the United States contributed the most instances, and Italy the least in 2021. How to Circumvent the Challenges? Antimicrobial stewardship is a program that encourages the responsible use of antibiotics to prevent resistance, one of the most important public health concerns in the United States. Concerns about greater rates of azithromycin and ceftriaxone resistance, when administered at lower doses, led to the recommendation of the revised updates. Other alternative regimens, such as azithromycin 1 g orally in a single dosage or levofloxacin 500 mg once daily for 7 days, are also advised to prevent the emergence of antibiotic resistance in addition to doxycycline 100 mg twice daily for 7 days. Notably, there is a doxycycline delayed-release (DR) formulation on the market to lessen pill burden and treat gastrointestinal issues. As part of this regimen, one doxycycline tablet of 200 mg should be taken every day for seven days. Although more expensive, this formulation is equally as potent as the immediate release formulation. Additionally, Ofloxacin (but not all other quinolones) is efficient in treating chlamydia. Erythromycin is typically thought of as a fallback chlamydia treatment for people who are unable to adhere to another regimen. Furthermore, in several countries and regions, including UK and US, Chlamydia screening is implemented to reduce the risk. All women who are under the age of 25, pregnant and those who are at high risk of infection are advised to get screened for Chlamydia. Way Ahead An ongoing global burden and major public health problem is the range of ocular, vaginal, and respiratory infections brought on by Gram-negative bacteria of the genus Chlamydia. The most prevalent conditions are conjunctivitis and blinding trachoma, followed by non-gonococcal urethritis, cervicitis, pelvic inflammatory illness, ectopic pregnancy, tubal factor infertility, and interstitial pneumonia. The current medical opinion is that an effective prophylactic vaccination is the best approach to protect people from chlamydial infections. This opinion resulted from failures in chlamydia screening and other preventive programs. There is no human chlamydia vaccine despite established animal immunizations. A significant problem has been the correct administration of vaccine antigens to generate secure and efficient immune effectors that provide long-term protective immunity. The development of biodegradable polymeric nanoparticles and derivatives that have been adjuvanted could speed the dream of human immunization in the near future. Related Reports: Diagnostic Imaging Equipment Market Diagnostic Imaging Equipment Market By Product (X-Ray Imaging Systems, Computed Tomography (CT) Scanners, Ultrasound Systems, Magnetic Resonance Imaging (MRI) Systems, Nuclear Imaging Systems, Mammography Systems, And Others), By Application (Cardiology, Oncology, Gastroenterology, Gynecology, And Other Applications), By End-User (Hospitals, Diagnostic Imaging Centres, And Others), by geography is expected to grow at a steady CAGR forecast till 2026 owing to rising technological advancement and increasing prevalence of chronic diseases.

3. Invasive Candidiasis Market "DelveInsight’s ‘Invasive Candidiasis Market Insight, Competitive Landscape and Market Forecast, 2027’ report delivers an in-depth understanding of Invasive Candidiasis and the historical and forecasted Invasive Candidiasis market trends, globally, which comprises of North America, Europe, APAC, and RoW. Sialidosis Market DelveInsight's "Sialidosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Sialidosis, historical and forecasted epidemiology as well as the Sialidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Filgrastim Biosimilar Insight DelveInsight’s, “Filgrastim Biosimilar Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Ventricular Assist Devices (VAD) Market Ventricular Assist Devices (VAD) Market By Type Of Devices (Neuromodulation & Neurostimulation Devices, Analgesic Infusion Pumps [Intrathecal Infusion Pumps and External Infusion Pumps], Ablation Devices [Radiofrequency Ablation Devices And Cryoablation Devices], And Others), By Application (Neuropathic Pain, Cancer Pain, Facial & Migraine Pain, Musculoskeletal Pain, and Others), By Geography is expected to grow at a steady CAGR Forecast till 2027 Latest Reports by DelveInsight Basal Cell Carcinoma Market | Birch Allergy Market | Bile Duct Neoplasm Market | Gingivitis Market | Lupus Nephritis Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Severe Hypertriglyceridemia (SHTG) Market | Arthralgia Market | Congestive Heart Failure Market | Gingivitis Market | Lupus Nephritis Market | Erythromelalgia Market | AL Amyloidosis Market | Primordial Dwarfism Market | Breast Pumps Market | Hyperuricemia Market | Helicobacter Pylori (H. pylori) Infection Market | AIDS Dementia- Market | Follicular Lymphoma Market | Chronic Pulmonary Hypertension Market | Adrenal Crisis Market | Retinoblastoma Market | Non-Cystic Fibrosis Bronchiectasis Market | Microsatellite Stable Colorectal Cancer Market | Chondrosarcoma Market | Sialidosis Market For more detailed information visit: https://www.delveinsight.com/eular-conference/eular-2022 To know more about our Competitive Services, Click here: Pharma Competitive Intelligence https://www.delveinsight.com/consulting/competitive-intelligence-services